Compare Stocks: SANA, TNGX, ELVN, and AMLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$33.00 +1.9%	$27.80	$10.83 ▼ $41.14	$3.61B	-0.13	1.65 million shs	1.36 million shs
ELVN Enliven Therapeutics	$48.19 -1.4%	$56.32	$14.78 ▼ $62.32	$3.58B	0.3	1.34 million shs	1.21 million shs
SANA Sana Biotechnology	$3.33 +7.4%	$3.49	$2.61 ▼ $6.55	$928.02M	2.12	3.38 million shs	6.95 million shs
TNGX Tango Therapeutics	$25.53 +14.3%	$25.44	$6.69 ▼ $34.39	$3.77B	1.12	2.38 million shs	6.97 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	+1.88%	-0.45%	-14.64%	+94.12%	+147.93%
ELVN Enliven Therapeutics	-1.39%	-9.69%	-19.44%	+0.88%	+141.92%
SANA Sana Biotechnology	+7.42%	+5.38%	-14.83%	+1.52%	+2.46%
TNGX Tango Therapeutics	+14.33%	+6.86%	+6.91%	-12.32%	+242.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$33.00 +1.9%	$27.80	$10.83 ▼ $41.14	$3.61B	-0.13	1.65 million shs	1.36 million shs
ELVN Enliven Therapeutics	$48.19 -1.4%	$56.32	$14.78 ▼ $62.32	$3.58B	0.3	1.34 million shs	1.21 million shs
SANA Sana Biotechnology	$3.33 +7.4%	$3.49	$2.61 ▼ $6.55	$928.02M	2.12	3.38 million shs	6.95 million shs
TNGX Tango Therapeutics	$25.53 +14.3%	$25.44	$6.69 ▼ $34.39	$3.77B	1.12	2.38 million shs	6.97 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	+1.88%	-0.45%	-14.64%	+94.12%	+147.93%
ELVN Enliven Therapeutics	-1.39%	-9.69%	-19.44%	+0.88%	+141.92%
SANA Sana Biotechnology	+7.42%	+5.38%	-14.83%	+1.52%	+2.46%
TNGX Tango Therapeutics	+14.33%	+6.86%	+6.91%	-12.32%	+242.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$38.86	17.75% Upside
ELVN Enliven Therapeutics	2.78	Moderate Buy	$75.00	55.63% Upside
SANA Sana Biotechnology	2.80	Moderate Buy	$9.33	180.28% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$43.46	70.24% Upside

Current Analyst Ratings Breakdown

Latest SANA, TNGX, ELVN, and AMLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$55.00 ➝ $57.00
8/24/2026	SANA Sana Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/19/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $55.00
8/19/2026	AMLX Amylyx Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$28.00 ➝ $52.00
8/18/2026	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $42.00
8/18/2026	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $55.00
8/18/2026	ELVN Enliven Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/18/2026	ELVN Enliven Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$78.00
8/18/2026	ELVN Enliven Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$62.00 ➝ $73.00
8/18/2026	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$66.00 ➝ $68.00
8/17/2026	AMLX Amylyx Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	42.08	N/A	N/A	$2.78 per share	11.87
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$7.74 per share	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A
TNGX Tango Therapeutics	$62.38M	69.01	N/A	N/A	$2.57 per share	9.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
ELVN Enliven Therapeutics	-$103.69M	-$1.67	N/A	N/A	N/A	N/A	-18.55%	-18.09%	11/11/2026 (Estimated)
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-103.02%	-39.16%	11/5/2026 (Estimated)
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-25.75%	-23.36%	11/3/2026 (Estimated)

Latest SANA, TNGX, ELVN, and AMLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A
8/10/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
8/5/2026	Q2 2026	ELVN Enliven Therapeutics	-$0.3872	-$0.49	-$0.1028	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
ELVN Enliven Therapeutics	N/A	64.07	64.07
SANA Sana Biotechnology	N/A	1.38	1.38
TNGX Tango Therapeutics	N/A	50.82	50.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
ELVN Enliven Therapeutics	95.08%
SANA Sana Biotechnology	88.23%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	10.90%
ELVN Enliven Therapeutics	3.00%
SANA Sana Biotechnology	25.40%
TNGX Tango Therapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	136	111.42 million	99.28 million	Optionable
ELVN Enliven Therapeutics	67	73.27 million	71.07 million	Optionable
SANA Sana Biotechnology	142	299.36 million	223.32 million	Optionable
TNGX Tango Therapeutics	137	168.61 million	157.65 million	Optionable

SANA, TNGX, ELVN, and AMLX Headlines

Recent News About These Companies

Tango Therapeutics (NASDAQ:TNGX) Trading 6% Higher - Here's Why

September 22 at 11:19 AM | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 22 at 4:15 AM | americanbankingnews.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Moderate Buy" from Analysts

September 22 at 4:13 AM | marketbeat.com

Squarepoint Ops LLC Sells 155,357 Shares of Tango Therapeutics, Inc. $TNGX

September 19, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 5.6% - Here's What Happened

September 18, 2026 | marketbeat.com

Tidal Investments LLC Purchases Shares of 55,384 Tango Therapeutics, Inc. $TNGX

September 18, 2026 | marketbeat.com

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

September 10, 2026 | zacks.com

Tango Therapeutics, Inc. $TNGX Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

September 10, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 9.5% - Still a Buy?

September 9, 2026 | marketbeat.com

Legal & General Group Plc Makes New $2.68 Million Investment in Tango Therapeutics, Inc. $TNGX

September 6, 2026 | marketbeat.com

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 3, 2026 | globenewswire.com

390,920 Shares in Tango Therapeutics, Inc. $TNGX Acquired by Bank of New York Mellon Corp

September 2, 2026 | marketbeat.com

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

September 1, 2026 | globenewswire.com

181,212 Shares in Tango Therapeutics, Inc. $TNGX Purchased by The Manufacturers Life Insurance Company

September 1, 2026 | marketbeat.com

Alyeska Investment Group L.P. Increases Holdings in Tango Therapeutics, Inc. $TNGX

September 1, 2026 | marketbeat.com

Nantahala Capital Management LLC Takes Position in Tango Therapeutics, Inc. $TNGX

August 29, 2026 | marketbeat.com

Jefferies Financial Group Inc. Makes New Investment in Tango Therapeutics, Inc. $TNGX

August 28, 2026 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by Brokerages

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Raises Stock Position in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Jupiter Topco LLC Invests $157.99 Million in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Boone Capital Management LLC Invests $14.24 Million in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA, TNGX, ELVN, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$33.00 +0.61 (+1.88%)

Closing price 09/22/2026 04:00 PM Eastern

Extended Trading

$33.00 0.00 (0.00%)

As of 07:08 AM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Enliven Therapeutics NASDAQ:ELVN

$48.19 -0.68 (-1.39%)

Closing price 09/22/2026 04:00 PM Eastern

Extended Trading

$48.25 +0.06 (+0.12%)

As of 04:34 AM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Sana Biotechnology NASDAQ:SANA

$3.33 +0.23 (+7.42%)

Closing price 09/22/2026 04:00 PM Eastern

Extended Trading

$3.31 -0.02 (-0.48%)

As of 07:09 AM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Tango Therapeutics NASDAQ:TNGX

$25.53 +3.20 (+14.33%)

Closing price 09/22/2026 04:00 PM Eastern

Extended Trading

$25.25 -0.28 (-1.10%)

As of 07:01 AM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SANA, TNGX, ELVN, and AMLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SANA, TNGX, ELVN, and AMLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SANA, TNGX, ELVN, and AMLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA, TNGX, ELVN, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Enliven Therapeutics NASDAQ:ELVN

Sana Biotechnology NASDAQ:SANA

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SANA, TNGX, ELVN, and AMLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SANA, TNGX, ELVN, and AMLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SANA, TNGX, ELVN, and AMLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA, TNGX, ELVN, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Enliven Therapeutics NASDAQ:ELVN

Sana Biotechnology NASDAQ:SANA

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools